Life Matters is a preclinical-stage biopharmaceutical company focused on tackling antibiotic-resistant bacteria. The company has developed a new solution for fighting the resistant bacteria often acquired in hospitals by preventing the bacterias biofilm mode of growth, resulting in a more treatable infection. Morbidity and mortality in chronic lung infections are often tied to biofilm-related P. aeruginosa. Eliminating the bacterial biofilm enables the innate immune system to eradicate the infection. Life Matters small molecules do not possess any resistance-creating selective pressure, and its compounds are effective against a wide variety of gram negative and positive pathogens. The companys lead product is API, IBF-2, a compound with an innovative mechanism of action that can attenuate the biofilm mode of growth, a crucial phenotype that allows bacteria to survive environmental stresses such as antibacterial agents or the hosts immune system.